Total cost comparison in relapsed/refractory multiple myeloma

References

• Anderson KC, Kyle RA, Rajkumar SV, et al. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008;22:231-9
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Clinical practice guidelines in oncology: multiple myeloma. Version 1.2012. National Comprehensive Cancer Network, Fort Washington, PA. 2012. http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed 15 October 2012
   Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G. Complete response in myeloma: a Trojan horse? Blood 2006;108:2134
   Web of Science ®Google Scholar
• Kane RC, Bross PF, Farrell AT, et al. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8:508-13
   PubMed Web of Science ®Google Scholar
• Durie BGM. Role of new treatment approaches in defining treatment goals in multiple myeloma – the ultimate goal is extended survival. Cancer Treat Rev 2010;36(Suppl 2):S18-23
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information (NCBI). Multiple Myeloma. U.S. National Library of Medicine, Bethesda, MD. 2011. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001609/. Accessed 15 October 2012
   Google Scholar
• Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147-52
   PubMed Web of Science ®Google Scholar
• Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high-dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007;92:546-9
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-60
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Weber DM, Nieszvizky R, et al. Comparison of lenalidomide plus dexamethasone therapy used at first relapse versus later salvage therapy in relapsed or refractory multiple myeloma patients. J Clin Oncol 2009;27(15S): abstract 8594
   Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32
   PubMed Web of Science ®Google Scholar
• Kenney J. Advances in the management of multiple myeloma: implications for payers. Am Health Drug Benefits 2011;4(2 Suppl 4):S59-60
   Google Scholar
• Messori A, Maratea D, Nozzoli C, et al. The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information. Pharmacoeconomics 2011;29:269-85
   PubMed Web of Science ®Google Scholar
• Fullerton D, Huleatt H, Marantz J, et al. Treatment of relapsed myeloma: a budget impact model comparing single agent bortezomib with combination lenalidomide and high-dose dexamethasone. Presented at the Academy of Managed Care Pharmacy 2007 Educational Conference, Boston, MA, October 24-27, 2007
   Google Scholar
• Moeremans K, Annemans L. An update: health economics of managing multiple myeloma. Eur J Cancer 2006;42):1684-91
   PubMed Web of Science ®Google Scholar
• Gaultney JG, Redekop WK, Sonneveld P, et al. Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology. Eur J Cancer 2011;47:1458-67
   PubMed Web of Science ®Google Scholar
• Durie BG, Borrello I, Binder G, et al. Treatment cost comparison in relapsed multiple myeloma. Presented at the 13th International Myeloma Workshop, Paris, France, May 3-6, 2011
   Google Scholar
• Cook R. Economic and clinical impact of multiple myeloma to managed care. J Manag Care Pharm 2008;14(7 Suppl):19-25
   PubMed Web of Science ®Google Scholar
• Schey S, Higginson I. Cost-effectiveness of lenalidomide in multiple myeloma. Expert Rev Pharmacoecon Outcomes Res 2010;10:229-38
   PubMed Web of Science ®Google Scholar
• REVLIMID [prescribing information]. Summit, NJ: Celgene Corporation, 2010
   Google Scholar
• Velcade [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals, 2010
   Google Scholar
• Binder G, Harwin W, Stemkowski S, et al. Drug resource use and costs for novel agents in multiple myeloma. J Clin Oncol 2012;30(Suppl 15):abstract e18560
   Google Scholar
• Centers for Medicare & Medicaid Services. Payment allowance limits for Medicare part B drugs. CMS, Bethesda, MD. 2010. http://www.cms.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesPrice/downloads/October_2010_ASP_Pricing_File.zip. Accessed 15 October 2012
   Google Scholar
• Curtiss FR, Lettrich P, Fairman KA. What is the price benchmark to replace average wholesale price (AWP)? J Manag Care Pharm 2010;16:492-501
   Google Scholar
• US Bureau of Labor Statistics. Consumer Price Index, All Urban Consumers. US Bureau of Labor Statistics, Washington, DC. 2012. http://data.bls.gov/cgi-bin/surveymost?cu. Accessed 15 October 2012
   Google Scholar
• Wang S, Huang H, Ba-mancini A, et al. The cost-effectiveness of bortezomib plus melphalan and prednisone versus lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment for the initial treatment of multiple myeloma in the USA, poster, ISPOR May 2011, Baltimore, MD
   Google Scholar
• Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:57-65
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-40
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20
   PubMed Web of Science ®Google Scholar
• Armoiry X, Fagnani F, Benboubker L, et al. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study. J Clin Pharm Ther 2011;36:19-26
   PubMed Web of Science ®Google Scholar
• Koleva D, Cortelazzo S, Toldo C, et al. Healthcare costs of multiple myeloma: an Italian study. Eur J Cancer Care (Engl) 2011;20:330-6
   PubMed Web of Science ®Google Scholar
• Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 2011;14:836
   PubMed Web of Science ®Google Scholar
• Calhoun EA, Chiang C-H, Welshman EE, et al. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 2001;6:441-5
   PubMed Web of Science ®Google Scholar
• Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:1653-61
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Maroun J, Shah A. Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis. Support Care Cancer 2005;13:318-24
   PubMed Web of Science ®Google Scholar
• Tina Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 2007;110:678-85
   PubMed Web of Science ®Google Scholar
• White RR, Lenhart G, Singhal PK, et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics 2009;27:781-92
   PubMed Web of Science ®Google Scholar
• Eber M, Laxminarayan R, Perencevich E, et al. Clinical and economic outcomes attributable to health care–associated sepsis and pneumonia. Arch Intern Med 2010;170:347-53
   PubMed Web of Science ®Google Scholar
• Vickrey E, Allen S, Mehta J, et al. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009;115:229-32
   PubMed Web of Science ®Google Scholar
• Micromedex 2.0: RedBook Online. 2011: http://www.micromedex.com/index.html. Accessed 15 October 2012
   Google Scholar
• Physician’s Fee and Coding Guide. Duluth, GA: Mag Mutual, 2011
   Google Scholar
• Centers for Medicare & Medicaid Services. Hospital Outpatient PPS Addendum A. Centers for Medicare & Medicaid Services, Baltimore, MD, 2011. http://www.cms.gov/HospitalOutpatientPPS/AU/. Accessed 15 October 2012
   Google Scholar
• US Bureau of Labor Statistics. CPI Detailed Report - Data for October 2010. US Bureau of Labor Statistics, Washington, DC. 2010. http://www.bls.gov/cpi/cpid1010.pdf. Accessed 15 October 2012
   Google Scholar